BENZONATATE capsule

Riik: Ameerika Ühendriigid

keel: inglise

Allikas: NLM (National Library of Medicine)

Toimeaine:

Benzonatate (UNII: 5P4DHS6ENR) (Benzonatate - UNII:5P4DHS6ENR)

Saadav alates:

Stat Rx USA

INN (Rahvusvaheline Nimetus):

Benzonatate

Koostis:

Benzonatate 100 mg

Manustamisviis:

ORAL

Retsepti tüüp:

PRESCRIPTION DRUG

Näidustused:

Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage. Hypersensitivity to benzonatate or related compounds.

Toote kokkuvõte:

Benzonatate Capsules, USP are available as: Soft gelatin capsules, 100 mg (oval, yellow); bottle of 100 Imprint: A1. NDC# 65162-536-10 Soft gelatin capsules, 100 mg (oval, yellow); bottle of 500 Imprint: A1. NDC# 65162-536-50 Soft gelatin capsules, 200 mg (oblong, yellow); bottle of 100 Imprint: A2. NDC# 65162-537-10 Store at 25°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant container as defined in the USP. Manufactured by: Swiss Caps AG Hausenstrasse 35 CH-9533, Kirchberg, Switzerland Distributed by: Amneal Pharmaceuticals Glasgow, KY 42141 Rev. 09-2008

Volitamisolek:

Abbreviated New Drug Application

Toote omadused

BENZONATATE - BENZONATATE CAPSULE
STAT RX USA
----------
BENZONATATE CAPSULE, LIQUID FILLED
RX ONLY
DESCRIPTION
Benzonatate, a non-narcotic antitussive agent, is 2, 5, 8, 11, 14, 17,
20, 23, 26-nonaoxaoctacosan-28-yl
p-(butylamino) benzoate; with a molecular weight of 603.7.
Benzonatate Capsules, USP contain 100 mg or 200 mg of benzonatate,
USP.
Benzonatate Capsules also contain: D and C Yellow No. 10, gelatin,
glycerin, methylparaben sodium and
propylparaben sodium.
CLINICAL PHARMACOLOGY
Benzonatate acts peripherally by anesthetizing the stretch receptors
located in the respiratory passages,
lungs, and pleura by dampening their activity and thereby reducing the
cough reflex at its source. It
begins to act within 15 to 20 minutes and its effect lasts for 3 to 8
hours. Benzonatate has no inhibitory
effect on the respiratory center in recommended dosage.
INDICATIONS AND USAGE
Benzonatate acts peripherally by anesthetizing the stretch receptors
located in the respiratory passages,
lungs, and pleura by dampening their activity and thereby reducing the
cough reflex at its source. It
begins to act within 15 to 20 minutes and its effect lasts for 3 to 8
hours. Benzonatate has no inhibitory
effect on the respiratory center in recommended dosage.
CONTRAINDICATIONS
Hypersensitivity to benzonatate or related compounds.
WARNINGS
Severe hypersensitivity reactions (including bronchospasm,
laryngospasm and cardiovascular collapse)
have been reported which are possibly related to local anesthesia from
sucking or chewing the capsule
instead of swallowing it. Severe reactions have required intervention
with vasopressor agents and
supportive measures.
PRECAUTIONS
Benzonatate is chemically related to anesthetic agents of the
para-aminobenzoic acid class (e.g.,
procaine; tetracaine) and has been associated with adverse CNS effects
possibly related to a prior
sensitivity to related agents or interaction with concomitant
medication.
INFORMATION FOR THE PATIENT
Release of benzonatate from the capsule in the mouth can produce a
temporary